Every material Form 8-K CUMBERLAND PHARMACEUTICALS INC has filed with the SEC since August 28, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Cumberland Pharmaceuticals plans to submit a New Drug Application to the FDA for ifetroban as a treatment for cardiomyopathy associated with Duchenne muscular dystrophy, seeking Traditional Approval based on its FIGHT DMD trial and natural history data. The FDA raised concerns that the proposed data package may not be sufficient to show substantial evidence of efficacy and requested additional analysis, and the company states there is no assurance the FDA will accept the filing or approve the drug.
The 12-month Phase 2 FIGHT DMD trial showed a statistically significant 5.4% absolute improvement in left ventricular ejection fraction (p=0.002) versus a control group.
The FDA suggested a Phase 3, randomized, placebo-controlled trial earlier in the review process, and expressed concerns about the sufficiency of the proposed data package at a pre-NDA meeting held this fall.
The FDA granted the company's request for rolling review of the NDA, allowing completed sections to be submitted before the full application.
The planned submission includes safety data from more than 1,400 subjects across approximately 30 clinical studies of ifetroban.
Cumberland Pharmaceuticals announced top-line results from its Phase 2a ASSIST-SSc trial of oral ifetroban in patients with systemic sclerosis, a rare disease. The company said the results support the drug's safety and tolerability in this population. The filing does not include efficacy data, financial figures, or guidance.
Trial: Phase 2a ASSIST-SSc evaluating oral ifetroban for systemic sclerosis
Announced October 23, 2026, with the press release furnished as Exhibit 99.1
Company states results support safety and tolerability of ifetroban in this rare disease population
Cumberland Pharmaceuticals said long-term safety and efficacy data from the open-label extension of its Phase 2 FIGHT DMD trial of ifetroban, an oral therapy for Duchenne muscular dystrophy heart disease, is not yet available. The company no longer expects to present the data in August 2026 and intends to present it at a future date. The filing is a schedule update that gives no new trial results.
The data was previously expected to be presented in August 2026, as shown on a slide at the June 26, 2026 Parent Project Muscular Dystrophy conference in Orlando, Florida.
The company says the data is not yet available and no longer expects to present it in August 2026.
No new response, safety or efficacy results were disclosed; no future date was given.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every CUMBERLAND PHARMACEUTICALS INC filing is on SEC EDGAR ↗. 8-K briefs of other companies →